|
WO2010085638A1
|
|
Olefin metathesis catalytic system
|
|
WO2010033466A1
|
|
Macrocyclic inhibitors of hepatitis c protease
|
|
WO2009152051A1
|
|
Synthesis of a macrocyclic hcv protease inhibitor
|
|
WO2009094462A1
|
|
A crystalline synthetic intermediate for pyrrolidin-3-yl-glycylaminoalkylboronates
|
|
WO2009091663A1
|
|
Stable pharmaceutical formulation of a dpp-iv inhibitor with metformin
|
|
WO2009017954A1
|
|
Inhibitors of jak2 kinase
|
|
WO2009009751A1
|
|
A crystalline synthetic intermediate for preparation of a dpp-iv inhibitor and method of purification thereof
|
|
BRPI0811845A2
|
|
Dosage form, and methods for preparing dosage, and treatment of a bad condition in a patient
|
|
EP2173709A2
|
|
Methods and intermediates for synthesis of selective dpp-iv inhibitors
|
|
US2010087658A1
|
|
Methods and intermediates for synthesis of selective dpp-iv inhibitors
|
|
AU2008205116A1
|
|
Macrocyclic hepatitis C protease inhibitors
|
|
US2010120716A1
|
|
Macrocyclic hepatitis c serine protease inhibitors and uses therefor
|
|
CA2661776A1
|
|
Solid citrate and tartrate salts of dpp-iv inhibitors
|
|
NZ575756A
|
|
Solid citrate and tartrate salts of 1-(2-[pyrrolidin-3-ylamino]-acetyl)-pyrrolidine-2-boronic acid.
|
|
AU2007201757A1
|
|
Heterocyclic boronic acid compounds
|
|
EP2029153A2
|
|
Hepatitis c serine protease inhibitors and uses therefor
|
|
EP1915382A2
|
|
Hepatitis c serine protease inhibitors and uses therefor
|
|
MX2008001612A
|
|
Methods of preparing hetercyclic boronic acids and derivatives thereof.
|
|
US2006264401A1
|
|
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US2006264400A1
|
|
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
